Markets:

Overview

News

Currencies

International

Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

0.4245 +0.0342 (+8.76%)

Streaming Delayed Price Updated: 2:33 PM EST, Nov 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗

November 06, 2023

DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court

Via Benzinga

Topics Economy

Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗

October 29, 2023

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Via Benzinga

Topics Intellectual Property

Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗

October 22, 2023

Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts

Via Benzinga

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗

October 16, 2023

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results of Preclinical Study to Advance SPU-21

October 16, 2023

Via Investor Brand Network

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

October 16, 2023

From Silo Pharma, Inc.

Via GlobeNewswire

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Initiates Human Factor Study of Its Targeted Prophylactic Treatment SPC-15

October 11, 2023

Via Investor Brand Network

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD

October 11, 2023

From Silo Pharma, Inc.

Via GlobeNewswire

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗

October 06, 2023

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

Via Benzinga

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

Stocks That Hit 52-Week Lows On Thursday ↗

September 21, 2023

During the session on Thursday, 461 stocks hit new 52-week lows.

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive SPC-15 Data, Plans to File Pre-IND Application

September 20, 2023

Via Investor Brand Network

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

September 20, 2023

From Silo Pharma, Inc.

Via GlobeNewswire

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗

September 18, 2023

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

Via Benzinga

NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years ↗

September 12, 2023

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Begin Feasibility Study of Proprietary Novel Intranasal Formulation for PTSD

September 12, 2023

Via Investor Brand Network

Topics Intellectual Property

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

September 12, 2023

From Silo Pharma, Inc.

Via GlobeNewswire

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗

September 05, 2023

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

Via Benzinga

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗

August 28, 2023

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗

August 28, 2023

Via Benzinga

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗

August 21, 2023

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds

Via Benzinga

Topics Cannabis Economy

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Strategic Engagement to Step up IP and Patent Expansion Efforts

August 10, 2023

Via Investor Brand Network

Topics Intellectual Property

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

August 10, 2023

From Silo Pharma, Inc.

Via GlobeNewswire

Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment ↗

August 08, 2023

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug...

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Significant Development Advancement of SPC-15

August 08, 2023

Via Investor Brand Network

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 08, 2023

Via Benzinga

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders

August 08, 2023

From Silo Pharma, Inc.

Via GlobeNewswire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions